Not a long time ago this year, Biogen announced the halting of Phase III clinical trials, EMERGE and ENAGE, of its most looked upon drug aducanumab under simulations for the treatment of Alzheimer's disease called futility analysis.
The drug was designed to help patients struggling with mild cognitive impairment and mild dementia due to Alzheimer’s disease. The failure of the trials to produce positive results and failure to meet the primary end-point led the Biogen and Eisai to decide on halting the further analysis of aducanumab.
Shockingly enough, Biogen has revived the hopes
of several patients by announcing the resurrection of its long-lost drug. The
comp...
